MU Stage1 Final Rule - Drug-Drug Drug-Allergy Checks

SECTION # Section 170.302(a)—Drug-Drug, Drug-Allergy, Drug-Formulary Checks

MU OBJECTIVE Implement drug-drug and drug-allergy interaction checks

MU STAGE 1 MEASURE The EP/eligible hospital/CAH has enabled this functionality for the entire EHR reporting period

CERTIFICATION CRITERION Final Rule Text: §170.302(a). (1) Notifications. Automatically and electronically generate and indicate in real-time, notifications at the point of care for drug- drug and drug-allergy contraindications based on medication list, medication allergy list, and computerized provider order entry (CPOE). (2) Adjustments. Provide certain users with the ability to adjust notifications provided for drug-drug and drug-allergy interaction checks.

STANDARDS N/A

TEST CRITERIA # §170.302 (a) http://healthcare.nist.gov/docs/170.302.a_DrugDrugDrugAllergy_v1.0.pdf

USERS	CORE / MENU	SOLUTION DEVELOPERS	STATUS
All	CORE	Oroville	In development

---

SOLUTION DESIGN / TECHNOLOGY (Add details here)

SOLUTION COMPONENTS (Add details here - Ex. KIDS patch, Delphi code, User guide, Web resources, Manual test script, etc)

DEPENDENCIES (Add details here)

COMMENTS / NOTES (Add details here)

PREVIOUS NOTES Note: VistA currently doesn't maintain formularies. This will need to be done with an interface to a 3rd party application, such as the NewCrop ePrescibing service. Drug interactions are handled in VistA but because of the additional requirements, the cur

DEVELOPMENT STATUS (Add details here)

ACTION ITEMS / NEXT STEPS (Add details here)

OPEN ISSUES / QUESTIONS (Add details here)